Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 143Myelodysplastic Syndromes 142Leukemia, Lymphocytic, Chronic, B-Cell 139Leukemia 127Multiple Myeloma 117Lymphoma 115Lymphoma, Non-Hodgkin 112Recurrence 78Hematologic Neoplasms 74Melanoma 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Hodgkin Disease 67Lymphoma, B-Cell 61Lymphoma, Mantle-Cell 51Lymphoma, Large B-Cell, Diffuse 50Lymphoma, Follicular 50Burkitt Lymphoma 41Ovarian Neoplasms 39Neoplasms 39Myeloproliferative Disorders 39Neoplasm Metastasis 33Lymphoma, B-Cell, Marginal Zone 30Graft vs Host Disease 29Neoplasms, Plasma Cell 28Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 27Leukemia, Biphenotypic, Acute 25Primary Myelofibrosis 24Anemia, Refractory, with Excess of Blasts 23

Interventions

tebentafusp 1pembrolizumab 1fludarabine 1atezolizumab 1Interleukin-2 1Drug Therapy 1Cyclophosphamide 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Select Advanced Solid Tumors × fludarabine × Clear all
NCT06598371 2026-05-20

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
141 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡